Vonjo

Active Ingredient(s): Pacritinib
FDA Approved: * February 28, 2022
Pharm Company: * CTI BIOPHARMA CORP
Category: Cancer

Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis.[1][2] It is a macrocyclic Janus kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3 (FLT3). Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs.[2] Contents 1 Medical uses 2 History 3 Society and culture 3.1 Names 4 References 5 External links Medical us... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.